Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis

randomised, double-blind controlled study

Giovanni Addolorato, Lorenzo Leggio, Anna Ferrulli, Silvia Cardone, Luisa Vonghia, Antonio Mirijello, Ludovico Abenavoli, Cristina D'Angelo, Fabio Caputo, Antonella Zambon, Paul S. Haber, Giovanni Gasbarrini

Research output: Contribution to journalArticle

417 Citations (Scopus)

Abstract

Background: Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver cirrhosis. Methods: Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than four drinks per day or overall consumption of 14 or more drinks per week over a period of at least 4 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00525252. Findings: Of 42 patients allocated baclofen, 30 (71%) achieved and maintained abstinence compared with 12 (29%) of 42 assigned placebo (odds ratio 6·3 [95% CI 2·4-16·1]; p=0·0001). The number of dropouts (termination of treatment) did not differ between the baclofen (6/42 [14%]) and placebo (13/42 [31%]) groups (p=0·12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62·8 [SE 5·4] vs 30·8 [5·5] days; p=0·001). No hepatic side-effects were recorded. Interpretation: Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals.

Original languageEnglish
Pages (from-to)1915-1922
Number of pages8
JournalLancet
Volume370
Issue number9603
DOIs
Publication statusPublished - Dec 8 2007

Fingerprint

Alcohol Abstinence
Baclofen
Double-Blind Method
Liver Cirrhosis
Maintenance
Alcohols
Safety
Placebos
Intention to Treat Analysis
Internal Medicine
Pharmaceutical Preparations
Italy
Liver Diseases
Outpatients
Therapeutics
Odds Ratio
Outcome Assessment (Health Care)
Recurrence
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis : randomised, double-blind controlled study. / Addolorato, Giovanni; Leggio, Lorenzo; Ferrulli, Anna; Cardone, Silvia; Vonghia, Luisa; Mirijello, Antonio; Abenavoli, Ludovico; D'Angelo, Cristina; Caputo, Fabio; Zambon, Antonella; Haber, Paul S.; Gasbarrini, Giovanni.

In: Lancet, Vol. 370, No. 9603, 08.12.2007, p. 1915-1922.

Research output: Contribution to journalArticle

Addolorato, G, Leggio, L, Ferrulli, A, Cardone, S, Vonghia, L, Mirijello, A, Abenavoli, L, D'Angelo, C, Caputo, F, Zambon, A, Haber, PS & Gasbarrini, G 2007, 'Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study', Lancet, vol. 370, no. 9603, pp. 1915-1922. https://doi.org/10.1016/S0140-6736(07)61814-5
Addolorato, Giovanni ; Leggio, Lorenzo ; Ferrulli, Anna ; Cardone, Silvia ; Vonghia, Luisa ; Mirijello, Antonio ; Abenavoli, Ludovico ; D'Angelo, Cristina ; Caputo, Fabio ; Zambon, Antonella ; Haber, Paul S. ; Gasbarrini, Giovanni. / Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis : randomised, double-blind controlled study. In: Lancet. 2007 ; Vol. 370, No. 9603. pp. 1915-1922.
@article{4337e99d70b54a8f99eae88d8a7207e6,
title = "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study",
abstract = "Background: Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver cirrhosis. Methods: Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than four drinks per day or overall consumption of 14 or more drinks per week over a period of at least 4 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00525252. Findings: Of 42 patients allocated baclofen, 30 (71{\%}) achieved and maintained abstinence compared with 12 (29{\%}) of 42 assigned placebo (odds ratio 6·3 [95{\%} CI 2·4-16·1]; p=0·0001). The number of dropouts (termination of treatment) did not differ between the baclofen (6/42 [14{\%}]) and placebo (13/42 [31{\%}]) groups (p=0·12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62·8 [SE 5·4] vs 30·8 [5·5] days; p=0·001). No hepatic side-effects were recorded. Interpretation: Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals.",
author = "Giovanni Addolorato and Lorenzo Leggio and Anna Ferrulli and Silvia Cardone and Luisa Vonghia and Antonio Mirijello and Ludovico Abenavoli and Cristina D'Angelo and Fabio Caputo and Antonella Zambon and Haber, {Paul S.} and Giovanni Gasbarrini",
year = "2007",
month = "12",
day = "8",
doi = "10.1016/S0140-6736(07)61814-5",
language = "English",
volume = "370",
pages = "1915--1922",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9603",

}

TY - JOUR

T1 - Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis

T2 - randomised, double-blind controlled study

AU - Addolorato, Giovanni

AU - Leggio, Lorenzo

AU - Ferrulli, Anna

AU - Cardone, Silvia

AU - Vonghia, Luisa

AU - Mirijello, Antonio

AU - Abenavoli, Ludovico

AU - D'Angelo, Cristina

AU - Caputo, Fabio

AU - Zambon, Antonella

AU - Haber, Paul S.

AU - Gasbarrini, Giovanni

PY - 2007/12/8

Y1 - 2007/12/8

N2 - Background: Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver cirrhosis. Methods: Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than four drinks per day or overall consumption of 14 or more drinks per week over a period of at least 4 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00525252. Findings: Of 42 patients allocated baclofen, 30 (71%) achieved and maintained abstinence compared with 12 (29%) of 42 assigned placebo (odds ratio 6·3 [95% CI 2·4-16·1]; p=0·0001). The number of dropouts (termination of treatment) did not differ between the baclofen (6/42 [14%]) and placebo (13/42 [31%]) groups (p=0·12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62·8 [SE 5·4] vs 30·8 [5·5] days; p=0·001). No hepatic side-effects were recorded. Interpretation: Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals.

AB - Background: Intervention to achieve alcohol abstinence represents the most effective treatment for alcohol-dependent patients with liver cirrhosis; however, anticraving drugs might worsen liver disease. We aimed to investigate the effectiveness and safety of baclofen in achieving and maintaining alcohol abstinence in patients with liver cirrhosis. Methods: Between October, 2003, and November, 2006, 148 alcohol-dependent patients with liver cirrhosis were referred to the Institute of Internal Medicine, Rome, Italy. 84 were randomly allocated either oral baclofen or placebo for 12 weeks. Primary outcome was proportion of patients achieving and maintaining alcohol abstinence. Measures of this outcome were total alcohol abstinence and cumulative abstinence duration, which were assessed at outpatient visits. Relapse was defined as alcohol intake of more than four drinks per day or overall consumption of 14 or more drinks per week over a period of at least 4 weeks. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00525252. Findings: Of 42 patients allocated baclofen, 30 (71%) achieved and maintained abstinence compared with 12 (29%) of 42 assigned placebo (odds ratio 6·3 [95% CI 2·4-16·1]; p=0·0001). The number of dropouts (termination of treatment) did not differ between the baclofen (6/42 [14%]) and placebo (13/42 [31%]) groups (p=0·12). Cumulative abstinence duration was about twofold higher in patients allocated baclofen than in those assigned placebo (mean 62·8 [SE 5·4] vs 30·8 [5·5] days; p=0·001). No hepatic side-effects were recorded. Interpretation: Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis. The drug is well tolerated and could have an important role in treatment of these individuals.

UR - http://www.scopus.com/inward/record.url?scp=36549086809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549086809&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(07)61814-5

DO - 10.1016/S0140-6736(07)61814-5

M3 - Article

VL - 370

SP - 1915

EP - 1922

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9603

ER -